These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9692133)

  • 21. Tetany: a complication of cis-dichlorodiammineplatinum(II) therapy.
    Hayes FA; Green AA; Senzer N; Pratt CB
    Cancer Treat Rep; 1979 Apr; 63(4):547-8. PubMed ID: 445508
    [No Abstract]   [Full Text] [Related]  

  • 22. Ototoxicity of aminoglucoside antibiotics in long-term treatment for cystic fibrosis.
    Crifo S; Antonelli M; Gagliardi M; Lucarelli N; Marcolini P
    Int J Pediatr Otorhinolaryngol; 1980 Sep; 2(3):251-3. PubMed ID: 6821312
    [No Abstract]   [Full Text] [Related]  

  • 23. Tetany following phosphate enemas in chronic renal disease.
    Chesney RW; Haughton PB
    Am J Dis Child; 1974 Apr; 127(4):584-6. PubMed ID: 4821324
    [No Abstract]   [Full Text] [Related]  

  • 24. Hypocalcemia, hypomagnesemia and hypokalemia during chemotherapy of pulmonary tuberculosis.
    Vanasin B; Colmer M; Davis PJ
    Chest; 1972 May; 61(5):496-9. PubMed ID: 4340029
    [No Abstract]   [Full Text] [Related]  

  • 25. No hearing loss after repeated courses of tobramycin in cystic fibrosis patients.
    Scheenstra RJ; Heijerman HG; Zuur CL; Touw DJ; Rijntjes E
    Acta Otolaryngol; 2010 Feb; 130(2):253-8. PubMed ID: 19479457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
    Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
    Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements.
    Chuchalin A; Amelina E; Bianco F
    Pulm Pharmacol Ther; 2009 Dec; 22(6):526-32. PubMed ID: 19616111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis.
    Staubes BA; Metzger NL; Walker SD; Peasah SK
    Pharmacotherapy; 2016 Jun; 36(6):623-30. PubMed ID: 27138730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypomagnesaemic tetany associated with prolonged treatment with aminoglycosides.
    Kelnar CJ
    Br Med J (Clin Res Ed); 1986 Apr; 292(6526):1017. PubMed ID: 3083971
    [No Abstract]   [Full Text] [Related]  

  • 30. Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients.
    Stehling F; Büscher R; Grosse-Onnebrink J; Hoyer PF; Mellies U
    Pulm Med; 2017; 2017():2602653. PubMed ID: 28133546
    [No Abstract]   [Full Text] [Related]  

  • 31. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis.
    Bragonier R; Brown NM
    J Antimicrob Chemother; 1998 Jul; 42(1):103-6. PubMed ID: 9700537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amikacin-induced hypomagnesaemic tetany complicating multidrug-resistant tuberculosis treatment.
    Dauby N; Payen MC
    Int J Tuberc Lung Dis; 2010 May; 14(5):657-8. PubMed ID: 20392363
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
    van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM
    J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary magnesium leak complicating treatment of choriocarcinoma.
    Moloney A; Eastwood JB; de Wardener HE
    Nephron; 1982; 30(1):51-55. PubMed ID: 7201083
    [No Abstract]   [Full Text] [Related]  

  • 35. Amphotericin B, aminoglycosides, and hypomagnesaemic tetany.
    Davies SV; Murray JA
    Br Med J (Clin Res Ed); 1986 May; 292(6532):1395-6. PubMed ID: 3085862
    [No Abstract]   [Full Text] [Related]  

  • 36. Monitoring of tobramycin levels in patients with cystic fibrosis by finger-prick sampling.
    Jones A; Beisty J; McKenna D; Clough D; Webb K; Morris J; Keevil B
    Eur Respir J; 2012 Jun; 39(6):1537-8. PubMed ID: 22654009
    [No Abstract]   [Full Text] [Related]  

  • 37. Tobramycin-induced aquagenic wrinkling of the palms in a patient with cystic fibrosis.
    Ludgate MW; Patel D; Lamb S
    Clin Exp Dermatol; 2009 Jul; 34(5):e75-7. PubMed ID: 19438544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tobramycin dosing in cystic fibrosis.
    Smyth A; Touw D; Tan KH; Bertenshaw C; Stableforth D
    Lancet; 2005 May 21-27; 365(9473):1767-8. PubMed ID: 15910946
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluation of long term tobramycin therapy in patients with cystic fibrosis and advanced pulmonary disease.
    Paporisz U; Posselt HG; Wönne R; Ristow W; Röser D; Knothe H; Bender SW
    Eur J Pediatr; 1979 Apr; 130(4):259-69. PubMed ID: 436850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.